Clolar Approval History

• FDA approved: Yes (First approved December 28th, 2004)
• Brand name: Clolar
• Generic name: clofarabine
• Company: Genzyme Corp.
• Treatment for: Acute Lymphoblastic Leukemia

Clolar (clofarabine) is a purine nucleoside anti-metabolite indicated for the treatment of children with refractory or relapsed acute lymphoblastic leukemia (ALL).

FDA Approval History for Clolar

Date	Article
Dec 28, 2004	Clolar Genzyme Corp. - Treatment for Leukemia in Children
Dec  1, 2004	FDA Advisory Committee Recommends Accelerated Clofarabine Approval for Most Common Pediatric Leukemia; FDA to Make Approval Decision by End of Year
Sep 28, 2004	ILEX's Clofarabine Scheduled For FDA Advisory Committee Review; ODAC to Review Pivotal Data for Pediatric Acute Leukemia
Aug 24, 2004	ILEX Updates Clofarabine NDA with Encouraging Results; Additional Patient Data Resets FDA Action Date
Jul 21, 2004	FDA Will Grant ILEX's Clofarabine Additional Six-Month Pediatric Exclusivity; Incentive Provides Extended Patent Protection Upon Marketing Approval
Jun  3, 2004	FDA Begins Priority Review of ILEX NDA for Clofarabine in Pediatric Acute Leukemia; Filing Acceptance Indicates Start of Official Review Period
Mar 31, 2004	ILEX Completes New Drug Application for Clofarabine; Filing Offers Hope to Children with Most Difficult-to-Treat Leukemias

See also...

Clolar (clofarabine) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.